| Literature DB >> 28427503 |
Bianca So1, Loredana Marcu2, Ian Olver3, Raghu Gowda4, Eva Bezak5.
Abstract
Oesophageal cancer is a relatively uncommon malignancy, but with poor prognosis. Despite several treatment options that are available, the 5-year survival rates rarely exceed 40%. This review discusses the main challenges of oesophageal cancer, the available treatment options, and the most effective treatment in terms of overall survival. The outcomes of clinical trials show that neo-adjuvant chemo-radiotherapy using cisplatin and 5-fluorouracil followed by oesophagectomy results in the greatest survival. However, the optimal chemotherapy and radiotherapy schedule remains unclear. There is no satisfactory treatment to date, particularly for patients with co-morbidities or advanced tumours.Entities:
Keywords: Chemotherapy; Cisplatin; Clinical trials; Radiotherapy
Mesh:
Year: 2017 PMID: 28427503 DOI: 10.1016/j.critrevonc.2017.03.004
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312